Infection Rates Regarding infection rates, the pooled analysis indicated no statistically significant difference between the AlloDerm and DermACELL groups, although the trend approached significance (RR = 1.32, 95% CI, 0.99-1.75, P = .06) for slightly higher rates with AlloDerm.
9 Swisher et al investigated outcomes between DermACELL and AlloDerm in breast reconstruction and found no significant differences in complication rates, including implant failure, skin necrosis, hematoma, and red breast syndrome, with the latter showing only a trend toward significance. 12 Their study included fewer studies, which may influence the breadth of data analysis.